**The contribution of *Pseudomonas aeruginosa* virulence factors and host factors in the establishment of urinary tract infections.**

**Newman JW, Floyd RV and Fothergill JL.**

1. **Department of Clinical Infection, Microbiology and Immunology, Institute of Infection and Global Health, University of Liverpool, UK.**
2. **Department of Cellular and Molecular Physiology, Institute of Translational Medicine, University of Liverpool, UK.**

**Abstract**

*Pseudomonas aeruginosa* can cause complicated urinary tract infections, particularly in people with catheters, which can lead to pyelonephritis. Whilst some subgroups appear more susceptible to infection, such as the elderly and women, the contribution of other host factors and bacterial virulence factors to successful infection remains relatively understudied. In this review we explore the potential role of *P. aeruginosa* virulence factors including phenazines, quorum sensing, biofilm formation, and siderophores along with host factors such as Tamm-Horsfall protein, osmotic stress and iron specifically on establishment of successful infection in the urinary niche. *P. aeruginosa* urinary tract infections are highly antibiotic resistant and require costly and intensive treatment. By understanding the infection dynamics of this organism within this specific niche, we may be able to identify novel therapeutic strategies to enhance the use of existing antibiotics.

**Introduction**

Urinary tract infections (UTI) are the most common healthcare acquired infection and account for over 30% of all nosocomial infections (Klevens *et al.* 2007). UTIs can be classified as uncomplicated or complicated. Uncomplicated UTI’s occur in patients with normal, healthy urinary tracts. Complicated UTIs occur in patients with structurally or functionally compromised urinary tracts, as seen in catheterized patients and patients suffering from pyelonephritis – bacterial ascension of the kidney (Gonzalez and Schaeffer 1999; Nicolle 2005). In uncomplicated UTI, *Escherichia coli* is the primary causative agent responsible for up to 80% of cases with other Gram negative microbes such as *Klebsiella pneumoniae* and *P. aeruginosa* being less frequently detected (7-15%) (Honkinen *et al.* 1999; Rizvi *et al.* 2011; Pobiega *et al.* 2016). However, complicated UTI are more frequently caused by uropathogenic (based on site of isolation) *P. aeruginosa*, which shows a higher prevalence of antimicrobial resistance and greater propensity to form biofilms on medical devices. *P. aeruginosa* urine sampleisolates from UTI patients in England, are more likely to be resistant to carbapenems than either *E. coli or K. pneumoniae* (Ironmonger *et al.* 2015).

Approximately 13% of *P. aeruginosa* infections are caused by multidrug resistant strains (CDC 2013) and nosocomial *P. aeruginosa* infections have been identified as a worldwide healthcare issue (Rosenthal *et al.* 2016). The World Health Organization has recently named *P. aeruginosa* as a target of the highest priority for the development of new antibiotics (WHO 2017). Infection by multidrug resistant *P. aeruginosa* was associated with a 70% increase in cost per patient when compared to non-resistant infection (Morales *et al.* 2012) and catheter associated UTIs (CAUTI) cause an estimated 900 000 extra hospital days per year in the United States (Warren 2001). Elderly populations are particularly prone to CAUTI in long term care facilities while women are more susceptible to UTIs in general (Nicolle, Strausbaugh and Garibaldi 1996; Foxman 2014). *P. aeruginosa* is often highly resistant to antibiotics. A study by Rizvi *et al.,* (2011) showed that *P. aeruginosa* isolates from UTIs in India were highly resistant to fluoroquinolones, (ciprofloxacin 85.8% resistant and ofloxacin 80.0% resistant) however no resistance to antibiotics such as imipenem was detected. High resistance to fluoroquinolones has also been reported in Poland, along with increased resistance to carbapenems (Pobiega *et al.* 2016). Many factors are responsible for the inherent resistance of *P. aeruginosa* to antimicrobials: a cell wall with low permeability, a large and adaptable genome, mobile genetic elements and the formation of biofilms (Lambert 2002). Some antibiotics manage to permeate the cell wall through porins e.g. carbapenems access through OprD porins. Loss of OprD porins can result in resistance to carbapenems (Livermore 2001; Lister, Wolter and Hanson 2009). Even antibiotics that manage to permeate the cell well of *P. aeruginosa* face being exported by one of the many efflux pumps present. Several antibiotic efflux systems have been described including MexAB-OprM, MexCD-OprJ, MexEF-OprN and MexXY-OprM (Poole 2001). Mutations in *gyrA* change the DNA gyrase targeted by quinolones resulting in resistance (Akasaka *et al.* 2001). Of the estimated 51,000 healthcare associated *P. aeruginosa* infections that occur in the United States every year, approximately 13% of them are multidrug resistant (CDC 2013). A test of 32 *P. aeruginosa* isolates from UTIs found that 19% of the strains were multi-drug resistant and growth in artificial urine media enhanced antibiotic tolerance up to 6000-fold (Narten *et al.* 2012). Therefore, current clinical practices of evaluating antibiotic resistance may underestimate enhanced resistance conferred by the biofilm lifestyle and adaptation to conditions in the urinary tract.

The pathogenesis of uropathogenic *Escherichia coli* (UPEC)-mediated UTI has been extensively characterized, but very little is known about the role of *P. aeruginosa* virulence factors and the interplay between bacteria and host factors found in the urinary tract.

*P. aeruginosa* is widely recognised as having an arsenal of virulence factors that help to facilitate successful infection and colonisation across a wide range of environments. For many bacteria the urinary tract represents a harsh, nutrient-limited environment; however, the versatility and size of *P. aeruginosa* genomes result in an ability to exploit this niche. This review will summarise the importance of *P. aeruginosa* virulence characteristics in the context of UTIs and the potential role of some of these virulence factors is described in Table 1.

**Siderophores**

Siderophores are iron chelating compounds that are secreted by bacteria and aid survival, especially in iron limited environments. Pyoverdine and pyochelin are siderophores produced by *P. aeruginosa* (Table 1). Pyoverdine is a group of green fluorescent compounds that represents the primary iron-uptake system in *P. aeruginosa*. Pyochelin has a lower affinity for iron compared to pyoverdine and has been proposed to be associated with sustained inflammatory responses identified in chronic infections (Cornelis and Dingemans 2013). Siderophores, particularly pyoverdine, are essential for virulence in many models of infection including lung infection and burn models (Visca, Imperi and Lamont 2007) however the role in UTIs is relatively unclear. A study by Tielen *et al*., (2011) revealed that pyoverdine could be detected in all 30 isolates from UTIs and CAUTIs were investigated and iron-limited conditions have been suggested to be important in UTIs. . Furthermore, microarray and qRT-PCR studies of other Gram negative microbes causing UTIs have shown dramatic upregulation of siderophore-related genes *in vivo* in humans and mice compared with *in vitro* growth in LB, suggesting that iron acquisition may also be essential in this niche (Reigstad, Hultgren and Gordon 2007). However, clinical isolates from the repiratory tract have also been found to produce pyoverdine and therefore this is not a niche-specific trait.

**Toxins**

*P. aeruginosa* can produce a variety of toxins, including four type III toxins; Exoenzyme (Exo) S, ExoU, ExoT and ExoY (Figure 1). *In vitro* expression of these toxins from isolates has been identified in *P. aeruginosa* isolates from various infection settings, particularly from acute infections (Hauser *et al.* 2002). Exo S is an effector protein of the type III secretion system and functions as an ADP-ribosylating enzyme (Iglewski *et al.* 1978). Levels of Exo S were significantly higher  *in vitro* in *P. aeruginosa* isolates from wound and urinary tract infections when compared to tracheal isolates (Hamood, Griswold and Duhan 1996) and increased with persistent infection. Infection isolates isolated longitudinally produced higher levels of Exo S, regardless of the site of infection (Hamood, Griswold and Duhan 1996; Rumbaugh, Griswold and Hamood 1999) suggesting a role for this enzyme in persistence. ExoU is a cytotoxin secreted by the type III secretion system. ExoU has phospholipase A2 activity and also impairs the recruitment of phagocytes (Diaz *et al.* 2008). The presence of exoU has been identified in isolates from the urinary tract however nothing is known about the potential role of ExoU in urinary tract infections and the roles of ExoT and ExoY are shown in Table 1.

**Exopolysaccharides and biofilm formation**

The ability of *P. aeruginosa* to form biofilms is an advantage in many infection situations and greatly enhances its ability to resist antibiotics and harsh environmental conditions. Exopolysaccharides, extracellular DNA (eDNA), pyocyanin, rhamnolipids and functional proteins are all factors that contribute to the formation of *P. aeruginosa* biofilms. Alginate, Pel and Psl are three polysaccharides produced by *P. aeruginosa*. High levels of alginate are commonly seen in Cystic Fibrosis isolates and these alginate over-producing strains are classified as mucoid. However, isolates from UTIs produce significantly lower levels of alginate in vitro when compared to isolates from various body sites (Ciragil and Söyletir 2004; Tielen *et al.* 2011; Rawat and Prasad 2015).

In non-mucoid strains there is a greater reliance on Pel and Psl. Psl is important in surface attachment of biofilms *in vitro* but there is functional redundancy between Pel and Psl (Colvin *et al.* 2012). Biofilms formed by *P. aeruginosa* in a murine model of CAUTI did not require exopolysaccharides (Cole *et al.* 2014). It has been proposed that another secreted virulence factor, pyocyanin, binds to, and intercalates with, eDNA thereby increasing the viscosity of DNA solutions(Das *et al.* 2015). This maypromotebiofilm formation via this route in the urinary tract (Figure 2). Pyocyanin can lead to the production of reactive oxygen species (ROS) and impaired wound healing (Figure 1). 5-Me-PCA, a precursor to pyocyanin, has even greater redox potential than pyocyanin and could be even more helpful to cells through theoretically supporting ATP generation in combination with electron donors such as succinate in the anoxic locations of the biofilm (Sakhtah *et al.* 2016).

Rhamnolipids promote microcolony formation in the early development of biofilms and in the late stages aid structural development that depends on cell migration (Pamp and Tolker-Nielsen 2007). Rhamnolipids rather than motility are responsible for the initiation of migration – termed seeding dispersal (Wang *et al.* 2013). Rhamnolipid expression is upregulated under iron limited environments and correlates with increased surface motility and the formation of flat, unstructured biofilms (Glick *et al.* 2010). Furthermore, rhamnolipid deficient *P. aeruginosa* cannot maintain the fluid-filled channels which are purported to aid nutrient diffusion through densely populated mature biofilms (Davey, Caiazza and O’Toole 2003). Since iron is thought to be limited in the urinary tract during infection, these qualities suggest that rhamnolipids could aid persistence of uropathogenic *P. aeruginosa* and enable ascension of the urinary tract. Rhamnolipid production could therefore be a key mediator of bacterial persistence in UTIs caused by *P. aeruginosa* (Figure 2)*.*

An operon of six genes (*fapABCDEF*) which encodes amyloid-like fimbriae(ALF) was found in *P. aeruginosa* and other Pseudomonads including *Pseudomonas fluorescens* (Dueholm *et al.* 2010). While the ALF in this strain were structurally similar to curli fimbriae purified from *E.* coli, the repeating 37 amino acid motifs found in FapC, the major subunit of the Fap fibril, were found to be distinct from those of *E.coli* curli. When the *fap* operon was expressed in *E. coli* it resulted in an aggregative phenotype, whereas the control strain of *E. coli* remained planktonic. Orthologues to the genes of the fap operon were found in *P. aeruginosa* (Dueholm *et al.* 2010) and over expression of this operon resulted in increased biofilm formation (Dueholm *et al.* 2013). The amyloid formed by the fap operon makes individual cells more resistant to drying, more hydrophobic and increases biofilm stiffness (Zeng *et al.* 2015). The hydrophobicity of amyloids enables binding of pyocyanin and the quorum sensing molecules, 2-heptyl-3-hydroxy-4(1H)-quinolone and N-(3-oxododecanoyl)-l-homoserine lactone (Seviour *et al.* 2015). Fap proteins have yet to be studied in relation to uropathogenic *P. aeruginosa*, but may play an important role – especially considering the diminished role of exopolysaccharides in UTI isolates.

**Other Secreted enzymes**

The majority of *P. aeruginosa* isolates are proteolytic and elastolytic (Nicas and Iglewski 1986). Proteolytic and elastolytic proteins are believed to contribute to the virulence and pathogenicity of *P. aeruginosa* (Figure 1*)*. The elastolysis-deficient mutant PAO-E64 demonstrated lower virulence than its PAO1 parent strain in a burned-mouse infection model (Nicas and Iglewski 1986) and rat-agar bead model of lung infection (Woods *et al.* 1982). From PAO-E64, the genes *lasA*, *lasB* and *aprA*, coding for LasA, elastase and alkaline protease, respectively, were implicated in proteolysis and elastolysis. LasA, like elastase and alkaline protease, has been shown to have its own elastolytic activity (Toder *et al.* 1994). Both *lasA* and *lasB* are transcriptionally regulated by lasR (Toder, Gambello and Iglewski 1991). In a study of tracheal, urinary tract and wound infections, high levels of elastase were seen in isolates studied *in vitro* from every site (Hamood, Griswold and Duhan 1996) suggesting that production is also beneficial during UTIs. The inability of a mutant PAO1 strain to colonize renal tissue in a mouse model was attributed to the mutant’s inability to produce protease, elastase and rhamnolipid (Gupta, Gupta and Harjai 2013).

*P. aeruginosa* has a haemolytic and non-haemolytic version of phospholipase C (PLC) – PlcH and PlcN, respectively (Ostroff, Vasil and Vasil 1990). Elevated levels of PlcH were detected in 100% of CF patients with chronic *P. aeruginosa* infections (Hollsing *et al.* 1987). PLC levels *in vitro* were higher in *P. aeruginosa* isolates from urinary tract infections, when compared to isolates from burns, wounds, CF sputum, pneumonia sputum and blood (Woods *et al.* 1986). However, in a study limited to isolates from tracheal, urinary tract and wound infections, PLC was highly produced at every site (Hamood, Griswold and Duhan 1996) and a more recent study rarely observed PLC (Tielen *et al.* 2011). While it is unclear whether there is a definitive role for PLC during UTI, it seems plausible that PLC-mediated red blood cell lysis and liberation of haem may provide a route for increased iron acquisition by bacteria, though further study is needed.

**Quorum sensing**

*P. aeruginosa* QS has been studied extensively and is currently proposed to consist of four interlinked QS systems; *las*, *rhl*, *pqs* and *iqs* . This has been reviewed recently (Lee and Zhang 2015). QS signal molecules (acyl homoserine lactones) are expressed constitutively. Once a threshold level of signal molecule, indicative of cell density, has been reached, coordinated gene expression is induced. In *P. aeruginosa*, approximately 10% of the genome is thought to be under the complex control of QS.

The *rhl* QS system is important in *P. aeruginosa* UTI pathogenesis with a PAO1 knockout of the *rhl* regulator, *rhlR,* showing significantly reduced virulence in a mouse model which could be restored through the addition of C4 homoserine lactone (Gupta, Harjai and Chhibber 2016). Bacteriological and histological assessment of mice infected with Δ*rhlR* PAO1 showed reduced bacterial load in the bladder and kidneys at Days 1, 3 and 5 post-infection compared to PAO1-infected control mice. Furthermore, *In vitro* the *rhlR* mutant showed significantly reduced expression of elastase (55.17%), protease (12.72%) and rhamnolipid (12.67%), essential virulence factors in *P. aeruginosa* pathogenicity, compared to wild-type PAO1. In an acute pyelonephritis model of infection, a QS deficient mutant (double *lasI* *rhlI* knockout) showed reduced inflammation and polymorphonuclear cell infiltration compared to the wild-type strain (Gupta *et al* 2013). QS activity was detected in all isolates from UTIs using a broad plate based assay and may suggest the importance of a functioning QS system in UTIs (Tielen *et al.* 2011). QS mutants are frequently found in *P. aeruginosa* isolates from the repiratory tract. *P. aeruginosa* with a defective QS system (double *lasI* *rhlI* knockout) has been shown to produce an altered, flatter biofilm (Davies *et al.* 1998) which may have an impact on the ability of the bacterium to form surface-attached CAUTI. *P. aeruginosa* biofilms from 14 out of 14 CAUTI isolates produced AHL’s when grown on catheters in a simple, physical model of a bladder and *in vitro* (Stickler *et al.* 1998).

In addition to the presence of an active QS system in *P. aeruginosa* isolates, QS signal molecules themselves induce renal tissue inflammation and cytokine response (Gupta, Chhibber and Harjai 2013) and affect the integrity of tight junctions in human epithelium (Vikström *et al.* 2009) although the effect on urothelium directly has not been studied (Figure 2).

**Motility**

Motility can be an important factor in allowing *P. aeruginosa* to colonise and exploit new niches. *P. aeruginosa* displays 3 types of motility; swimming, swarming and twitching. Swimming involves the rotation of a single polar flagellum. Swimming, through flagella movement, has been linked to triggering neutrophil extracellular traps (NETs) (Floyd *et al.* 2016) and phagocytosis by neutrophils (Lovewell, Patankar and Berwin 2014), the first line of defense in human infections. Twitching motility involves the extension and retraction of type IV pili and therefore play a vital role in bacterial attachment and initial colonisation, particularly on mucosal cell surfaces (Hahn 1997). In addition, type IV pili can further contribute to virulence and bacterial adaptation through the mediation of pil-dependent phage infection (Davies *et al.* 2016). Swarming motility requires multicellular coordination of bacteria across semi-solid (viscous) surfaces, including mucosal sites. The complex behaviour has been linked to increased antibiotic resistance and large shifts in bacterial gene expression (Overhage *et al.* 2008). The role of motility and downregulation of flagellin during chronic infection has been studied in isolates from CF lung infections (Mahenthiralingam, Campbell and Speert 1994) however, the role in UTIs is not known. Tielen *et al*., investigated swimming, twitching and swarming motility in *P. aeruginosa* isolates from UTIs. Over 90% of isolates displayed swimming activity and over 70% displayed twitching motility. The most variation in motility was seen in swarming. The ability to swarm was increased in isolates associated with UTIs compared to CAUTIs. Within the CAUTIS isolates, swarming was higher in acute CAUTIS compared to chronic CAUTIs. This may suggest that swarming motility is associated more with acute infection compared to chronic infection however the total number of isolates in this study was relatively limited (Tielen *et al.* 2011).

*P. aeruginosa* isolates from the urinary tract can produce a plethora of virulence factors however, many of these studies have studied the isolates under *in vitro* conditions and therefore the importance in vivo must be viewed with caution. In addition to known virulence factors, *P. aeruginosa* genomes carry an abundance of hypothetical proteins with unknown functions. It is possible that some of these may play important roles in infections and therefore there is much work to be performed to unlock this wealth of information.

**Host factors**

Certain patient groups display greater susceptibility to UTIs and there is an increased risk associated with being female (Finer and Landau 2004) and either very young (Jodal and Winberg 1987) or elderly (Nicolle, Strausbaugh and Garibaldi 1996; Foxman 2014). Complicated UTIs are often associated with structural and functional abnormalities of the urinary tract (Nicolle 2005). In addition to the risk factors above, genome wide association studies have identified several genes associated with increased risk to UTIs including mutations in DSTYK (Sanna-Cherchi *et al.* 2013), HSPA1B, CXCR1, CXCR2, TLR2, TLR4 and TGFB1 (Zaffanello *et al.* 2010). However these have been associated with UTIs in general and not *P. aeruginosa* specific.

In addition to host genetics, the urinary tract environment also plays a role in bacterial infections.

Tamm-Horsfall protein

Tamm-Horsfall protein (THP), also known as uromodulin, is a polymeric glycoprotein which can bind to a variety of surfaces by n-linked and o-linked glycans and is encoded by the *UMOD* gene (Pennica *et al.* 1987; Kumar and Muchmore 1990; Serafini-Cessi, Malagolini and Cavallone 2003). THP is produced in the thick ascending limb of the loop of Henle in the kidneys and is the most abundant protein in human urine. While most investigations of THP’s potential role in preventing UTIs focus on *E. coli*, these observations may also translate to other Gram negative uropathogens such as uropathogenic *P. aeruginosa,* given their overlapping virulence profiles and proposed mechanisms of pathogenicity (Figure 1). Studies suggest that bacterial clearance of *E. coli* from the urinary tract may be mediated by binding of type-1 fimbriaeto THP mannose moieties , thus preventing fimbrial adhesion to mannose-rich uroplakin Ia and Ib glycoproteins found in the uroepithelium. However the precise molecular interactions between THP and type-1 fimbriae are unclear.(Pak *et al.* 2001). These *in vitro* observations are further supported by *in vivo* studies of homozygous THP -/- knockout mice which are more vulnerable to bladder colonization by type 1 fimbriated *E. coli* (Bates *et al.* 2004). While type 1 fimbriae are not found in *P.* aeruginosa, other adhesive filaments such as type IV pili, are known to be important regulators of *E. coli* colonization in mouse-models of UTI and thus their presence in *P. aeruginosa* may contribute to UTI pathogenesis. The identity of the specific bacterial adhesins and host receptors that mediate adhesion of *P. aeruginosa* to epithelial cells in the urinary tract via Type IV pili are unclear. However, *P. aeruginosa* pili are known to bind to glycolipids expressed in epithelial cells with specificity towards the Galβ1-3GlcNAc and Galβ1-4GlcNAc residues. THP has been shown to be an excellent ligand for Galβ1-4GlcNAc active lectins, suggesting that THP may bind directly to type-IV pili and prevent *P. aeruginosa* adhering to host cells in a similar manner to that shown for type-1 fimbriae, albeit via a different glycoprotein.

While laboratory studies suggest that THP may have a protective role in preventing UTI, clinical findings in CAUTI patients may refute this evidence. Studies of both latex and silicone catheters removed from 20 patients had bound THP, with elevated levels detected on catheters colonized with bacteriacompared to culture negative samples. Given that silicone and latex catheters with bound THP facilitated binding of *E. coli* and *P. aeruginosa* (Raffi *et al.* 2009) this raises the possibility that catheters prevent THP-mediated elution of uropathogens thereby promoting UTIs.

The presence of THP at 50 μg ml-1 *in vitro* resulted in increased *P. aeruginosa* virulence factor production(protease, elastase, PLC, alginate, pyoverdin, pyochelin) *in vitro* compared to a control grown in the absence of THP. However, a further increase from 50 to 70 μg ml-1 resulted in a significant fall in measured virulence factor production suggesting that the effect is concentration dependent (Mittal *et al.* 2006). An increased renal load of *P. aeruginosa* was detected when the bacteria were coated with THP along with decreased adherence and killing of the coated bacteria by murine peritoneal macrophages (Harjai *et al.* 2005). In the event that *P. aeruginosa* manages to colonize the urinary tract (or the kidney where THP is membrane bound), THP could aid *P. aeruginosa* in evading the host immune system and increasing virulence (Hawthorn, Bruce and Reid 1991).

The normal range of excreted THP is 9.3-35.0 mg day-1 in males and 9.0-36.3 mg day-1 in females. The mean amount of THP excreted was significantly less in females (15.2 +/- 1.6 mg day-1) than in males (21.3 +/- 1.2 mg day-1) (Glauser *et al.* 2000).A common allelic variant of the *UMOD* gene associated with higher levels of excreted THP was found to correlate significantly with prevalence of antibiotic resistant UTIs. An inverse correlation between urinary levels of THP and markers of UTIs inthe general population supports the idea that the aforementioned UMOD variant has been kept at a high frequency because of its protective effect against UTIs (Ghirotto *et al.* 2016) and thus host genetics can play a role in susceptibility to infection. In a large study of community-living elderly patients, those with the highest urinary THP concentrations (upper quartile) were significantly less likely to develop a UTI than those with the lowest urinary THP concentrations (lower quartile) (Garimella *et al.* 2016). Small moleculecular weight mannosides that act in a similar way to THP, by inhibiting the have shown promise at combatting uropathogenic *E. coli* in a murine UTI model (Cusumano *et al.* 2011). . Future studies that characterise the molecular interactions that mediate type IV pilus binding to bladder cells and THP will lead the way for development of similar small molecule inhibitors that can disrupt binding of uropathogenic *P. aeruginosa* and thus prevent UTI.

Iron

Bacteria attempting to grow in the urinary tract experience conditions with very little iron (Shand *et al.* 1985). Growth of *P. aeruginosa* in iron-depleted medium decreased phagocytosis while enhancing adherence to uroepithelial cells and expression of all the major virulence factors compared to growth in iron-replete medium (Mittal *et al.* 2008a). Infection of mice with *P. aeruginosa* grown under iron-depleted conditions resulted in higher renal, bladder and urine bacterial counts as well as more extensive tissue damage compared to infection with *P. aeruginosa* grown under iron-replete conditions (Mittal *et al.* 2008a). To better understand how *P. aeruginosa* adapts to growth in the urinary tract, *P. aeruginosa* was grown anaerobically in artificial urine media (AUM) and analysed at a systems level using transcriptomics, proteomics, metabolomics and enzyme activity analyses (Tielen *et al.* 2013). 86 genes related to iron acquisition were active and upregulated when grown anaerobically in AUM compared to growth in 10-fold diluted LB broth (Tielen *et al.* 2013).

Osmotic stress

The human urinary tract experiences highly variable osmotic concentrations. Increasing the osmolarity of a growth medium from 100 to 300 mOsmol L-1 resulted in enhanced growth and virulence while further increase of osmolarity to 350 mOsmol L-1 resulted in significant reduction in growth and virulence of *P. aeruginosa* (Mittal *et al*. 2009). Typical osmolarity of human urine ranges from 500 to 800 mOsmol L-1. The aforementioned study suggests that there is a range of osmolarity that may predispose patients to UTI but further research is needed. Sequencing of a small colony variant of *P. aeruginosa* isolated from a chronic CAUTI highlighted the presence of several genes involved in osmotic stress protection such as a sodium/hydrogen ion antiporter (*nhaA*) and a compatible solute glycine betaine transporter (PAMH27\_5169 to PAMH27\_5171) (Tielen *et al.* 2014).

**Outlook**

The rise in antimicrobial resistant organisms is alarming and therefore there is a need to develop treatment strategies that minimize the selective pressures applied. In the case of uropathogenic *P. aeruginosa* this could involve a focus on clearing bacteria from the urinary tract rather than killing them outright. However, this would still select for bacteria that could avoid clearance and survive in the urinary tract niche. A more realistic but challenging strategy is the development of new therapeutic targets and the appropriate combination of existing therapies to reduce selection for bacterium resistant to individual therapies.

Sublethal doses of antibiotics have been shown to enhance the formation of *P. aeruginosa* biofilms (Bagge *et al.* 2004; Hoffman *et al.* 2005). The majority of antibiotics are designed with planktonic bacteria in mind. In the future there needs to be a greater focus in targeting biofilms. Pyocyanin and eDNA make enticing therapeutic targets because of their aforementioned importance in biofilms of *P. aeruginosa* UTIs. Addition of 250 and 500 μM of the antioxidant glutathione decreased the intercalation of pyocyanin with DNA in a DNA-pyocyanin mixture (Das *et al.* 2015). Confocal microscopy showed that the biofilms of PA14 had significantly lower surface coverage when grown in the presence of DNase I (Das *et al.* 2015) and therefore combining these biofilm inhibitors with traditional antibiotics may enhance treatment outcomes.

Oxidative stress occurs when damaging free radicals outnumber antioxidants and can cause tissue damage. Pyocyanin has been shown to induce oxidative stress in human endothelial cells by the generation of hydrogen peroxide. This depletes levels of glutathione, an antioxidant, and increases oxidative stress (Muller 2002). Urethral infection of mice with *P. aeruginosa* resulted in increased levels of reactive nitrogen intermediates, reactive oxygen species and tissue damage while reducing antioxidant capacity. Levels of oxidative stress, and associated biomarkers, were reduced when infected mice were treated with the antioxidant N-acetylcysteine (Mittal *et al.* 2008b). There are many other antioxidants that could be used to treat uropathogenic *P. aeruginosa* which have shown promise in treating other uropathogens (Allameh and Salamzadeh 2016).

Many other novel therapeutic strategies are under development including small molecule inhibitors, phytochemicals, antibody based therapy, bacteriophage therapy, photodynamic therapy, antimicrobial peptides, enzyme based therapy and nanoparticles (Sharma *et al.* 2014). Through understanding the factors that are important for virulence within the urinary tract, it may be possible to develop effective treatments aimed at reducing *P. aeruginosa* pathogenesis within this understudied niche.

**Contributions**

JN, RF and JF contributed equally to the conception, planning and writing of this manuscript.

**Acknowledgements**

JN, RF and JF would like to acknowledge funding received from Mersey Kidney First. RF is funded by a Kidney Research UK fellowship.

**Figure Legends**

Figure 1. Schematic representation of urothelium-*Pseudomonas aeruginosa* interactions and their effects on host cell physiology in urinary tract infections. *P. aeruginosa* possesses a broad array of virulence factors that facilitate colonization and propagation of infection. *P. aeruginosa* is known to express 4 type III secretion system (T3SS) effector proteins (ExoS, ExoU, ExoT and ExoY) which are delivered into host cells during infection. ExoU facilitates phagocyte killing and in conjunction with ExoT is known to activate pro-apoptotic pathways and delay wound healing in other epithelial cell types. ExoS may aid persistence and immune evasion via cytoskeletal disruption, enabling *P. aeruginosa* to act as an intracellular pathogen. While ExoY is also known to cause actin cytoskeletal disruption, its specific role in UTI is unclear. Other secreted virulence determinants such as proteolytic and elastolytic proteins, LasA and LasB are known to cause tissue damage and facilitate persistence in chronic infections. *P. aeruginosa* produces several phenazines that enhance competitiveness in polymicrobial infections. One such example, pyocyanin (PCN), is found in higher levels in urinary isolates than other infections and reduces urothelial cell viability via a mechanism thought to be regulated by induction of oxidative stress via generation of reactive oxygen species (ROS) which increase transcription of IL-6. PCN causes urothelial cell senescence which may play a role in impaired wound healing in chronic infections. Tamm-Horsfall proteins (THP) are also implicated as a secreted host-factor that enhances the virulence of *P. aeruginosa* in CAUTI, enhancing persistence and immune evasion.

Figure 2. Proposed model for biofilm formation of *Pseudomonas aeruginosa* capable of causing urinary tract infections (UTIs) and catheter-associated urinary tract infections (CAUTIs). *P. aeruginos*a is capable of causing infection both in the presence and absence of a urinary catheter. Pyocyanin (PCN) is thought to facilitate cross-linking of extracellular DNA (eDNA) leading to increased viscosity that facilitate initial biofilm formation. Secreted rhamnolipids (RHLD) promotes microcolony formation early in biofilm formation and aids structural integrity as development progresses. Within the biofilm, increased levels of quorum sensing occur and the signalling moleculaes, acyl-homoserine lactones (AHLs) may interact directly with the urothelium to decrease the integrity of tight junctions.

**References**

Akasaka T, Tanaka M, Yamaguchi A *et al.* Type II topoisomerase mutations in fluoroquinolone-resistant clinical strains of Pseudomonas aeruginosa isolated in 1998 and 1999: role of target enzyme in mechanism of fluoroquinolone resistance. *Antimicrob Agents Chemother* 2001;**45**:2263–8.

Allameh Z, Salamzadeh J. Use of antioxidants in urinary tract infection. *J Res Pharm Pract* 2016;**5**:79–85.

Bagge N, Schuster M, Hentzer M *et al.* Pseudomonas aeruginosa biofilms exposed to imipenem exhibit changes in global gene expression and beta-lactamase and alginate production. *Antimicrob Agents Chemother* 2004;**48**:1175–87.

Bates JM, Raffi HM, Prasadan K *et al.* Tamm-Horsfall protein knockout mice are more prone to urinary tract infection Rapid Communication. *Kidney Int* 2004;**65**:791–7.

Bitsori M, Maraki S, Koukouraki S *et al.* Pseudomonas Aeruginosa Urinary Tract Infection in Children: Risk Factors and Outcomes. *J Urol* 2012;**187**:260–4.

CDC. Antibiotic resistance threats in the United States, 2013. 2013.

Ciragil P, Söyletir G. Alginate, elastase and alkaline protease production of Pseudomonas aeruginosa strains isolated from various body sites. *Mikrobiyol Bul* 2004;**38**:341–7.

Cole SJ, Records AR, Orr MW *et al.* Catheter-Associated Urinary Tract Infection by Pseudomonas aeruginosa Is Mediated by Exopolysaccharide-Independent Biofilms. *Infect Immun* 2014;**82**:2048–58.

Colvin KM, Irie Y, Tart CS *et al.* The Pel and Psl polysaccharides provide Pseudomonas aeruginosa structural redundancy within the biofilm matrix. *Environ Microbiol* 2012;**14**:1913–28.

Cornelis P, Dingemans J. Pseudomonas aeruginosa adapts its iron uptake strategies in function of the type of infections. *Front Cell Infect Microbiol* 2013;**3**:75.

Cusumano CK, Pinkner JS, Han Z *et al.* Treatment and Prevention of Urinary Tract Infection with Orally Active FimH Inhibitors. *Sci Transl Med* 2011;**3**:109ra115-109ra115.

Das T, Kutty SK, Tavallaie R *et al.* Phenazine virulence factor binding to extracellular DNA is important for Pseudomonas aeruginosa biofilm formation. *Sci Rep* 2015;**5**:8398.

Davey ME, Caiazza NC, O’Toole GA. Rhamnolipid surfactant production affects biofilm architecture in Pseudomonas aeruginosa PAO1. *J Bacteriol* 2003;**185**:1027–36.

Davies DG, Parsek MR, Pearson JP *et al.* The involvement of cell-to-cell signals in the development of a bacterial biofilm. *Science* 1998;**280**:295–8.

Davies E V, James CE, Williams D *et al.* Temperate phages both mediate and drive adaptive evolution in pathogen biofilms. *Proc Natl Acad Sci U S A* 2016;**113**:8266–71.

Diaz MH, Shaver CM, King JD *et al.* Pseudomonas aeruginosa induces localized immunosuppression during pneumonia. *Infect Immun* 2008;**76**:4414–21.

Dueholm MS, Petersen SV, Sønderkaer M *et al.* Functional amyloid in Pseudomonas. *Mol Microbiol* 2010;**77**:no-no.

Dueholm MS, Søndergaard MT, Nilsson M *et al.* Expression of Fap amyloids in *Pseudomonas aeruginosa* , *P. fluorescens,* and *P. putida* results in aggregation and increased biofilm formation. *Microbiologyopen* 2013;**2**:365–82.

Finer G, Landau D. Pathogenesis of urinary tract infections with normal female anatomy. *Lancet Infect Dis* 2004;**4**:631–5.

Floyd M, Winn M, Cullen C *et al.* Swimming Motility Mediates the Formation of Neutrophil Extracellular Traps Induced by Flagellated Pseudomonas aeruginosa. Lee VT (ed.). *PLOS Pathog* 2016;**12**:e1005987.

Foxman B. Urinary Tract Infection Syndromes. *Infect Dis Clin North Am* 2014;**28**:1–13.

Garimella PS, Bartz TM, Ix JH *et al.* Urinary Uromodulin and Risk of Urinary Tract Infections: The Cardiovascular Health Study. *Am J Kidney Dis* 2016, DOI: 10.1053/j.ajkd.2016.08.022.

Ghirotto S, Tassi F, Barbujani G *et al.* The Uromodulin Gene Locus Shows Evidence of Pathogen Adaptation through Human Evolution. *J Am Soc Nephrol* 2016;**27**:2983–96.

Glauser A, Hochreiter W, Jaeger P *et al.* Determinants of urinary excretion of Tamm-Horsfall protein in non-selected kidney stone formers and healthy subjects. *Nephrol Dial Transplant* 2000;**15**:1580–7.

Glick R, Gilmour C, Tremblay J *et al.* Increase in rhamnolipid synthesis under iron-limiting conditions influences surface motility and biofilm formation in Pseudomonas aeruginosa. *J Bacteriol* 2010;**192**:2973–80.

Golan Y. Empiric therapy for hospital-acquired, Gram-negative complicated intra-abdominal infection and complicated urinary tract infections: a systematic literature review of current and emerging treatment options. *BMC Infect Dis* 2015;**15**:313.

Gonzalez CM, Schaeffer AJ. Treatment of urinary tract infection: what’s old, what’s new, and what works. *World J Urol* 1999;**17**:372–82.

Gupta P, Gupta R, Harjai K. Multiple virulence factors regulated by quorum sensing may help in establishment and colonisation of urinary tract by Pseudomonas aeruginosa during experimental urinary tract infection. *Indian J Med Microbiol* 2013;**31**:29.

Gupta R, Harjai K, Chhibber S. Rhl quorum sensing affects the virulence potential of Pseudomonas aeruginosa in an experimental urinary tract infection. *Antonie Van Leeuwenhoek* 2016;**109**:1535–44.

Gupta RK, Chhibber S, Harjai K. Quorum sensing signal molecules cause renal tissue inflammation through local cytokine responses in experimental UTI caused by Pseudomonas aeruginosa. *Immunobiology* 2013;**218**:181–5.

Hahn HP. The type-4 pilus is the major virulence-associated adhesin of Pseudomonas aeruginosa--a review. *Gene* 1997;**192**:99–108.

Hamood A, Griswold J, Duhan C. Production of Extracellular Virulence Factors byPseudomonas aeruginosaIsolates Obtained from Tracheal, Urinary Tract, and Wound Infections. *J Surg Res* 1996;**61**:425–32.

Harjai K, Mittal R, Chhibber S *et al.* Contribution of Tamm–Horsfall protein to virulence of Pseudomonas aeruginosa in urinary tract infection. *Microbes Infect* 2005;**7**:132–7.

Hauser AR, Cobb E, Bodi M *et al.* Type III protein secretion is associated with poor clinical outcomes in patients with ventilator-associated pneumonia caused by Pseudomonas aeruginosa. *Crit Care Med* 2002;**30**:521–8.

Hawthorn LA, Bruce AW, Reid G. Ability of uropathogens to bind to tamm horsfall protein-coated renal tubular cells. *Urol Res* 1991;**19**:301–4.

Hidalgo JA, Vinluan CM, Antony N. Ceftazidime/avibactam: a novel cephalosporin/nonbeta-lactam beta-lactamase inhibitor for the treatment of complicated urinary tract infections and complicated intra-abdominal infections. *Drug Des Devel Ther* 2016;**10**:2379–86.

Hoffman LR, D’Argenio DA, MacCoss MJ *et al.* Aminoglycoside antibiotics induce bacterial biofilm formation. *Nature* 2005;**436**:1171–5.

Hollsing AE, Granström M, Vasil ML *et al.* Prospective study of serum antibodies to Pseudomonas aeruginosa exoproteins in cystic fibrosis. *J Clin Microbiol* 1987;**25**:1868–74.

Honkinen O, Lehtonen OP, Ruuskanen O *et al.* Cohort study of bacterial species causing urinary tract infection and urinary tract abnormalities in children. *BMJ* 1999;**318**:770–1.

Iglewski BH, Sadoff J, Bjorn MJ *et al.* Pseudomonas aeruginosa exoenzyme S: an adenosine diphosphate ribosyltransferase distinct from toxin A. *Proc Natl Acad Sci U S A* 1978;**75**:3211–5.

Ironmonger D, Edeghere O, Bains A *et al.* Surveillance of antibiotic susceptibility of urinary tract pathogens for a population of 5.6 million over 4 years. *J Antimicrob Chemother* 2015;**70**:1744–50.

Jodal U, Winberg J. Management of children with unobstructed urinary tract infection. *Pediatr Nephrol* 1987;**1**:647–56.

Kanj SS, Kanafani ZA. Current Concepts in Antimicrobial Therapy Against Resistant Gram-Negative Organisms: Extended-Spectrum β-Lactamase–Producing Enterobacteriaceae, Carbapenem-Resistant Enterobacteriaceae, and Multidrug-Resistant Pseudomonas aeruginosa. *Mayo Clin Proc* 2011;**86**:250–9.

Klevens RM, Edwards JR, Richards CL *et al.* Estimating health care-associated infections and deaths in U.S. hospitals, 2002. *Public Health Rep* 2007;**122**:160–6.

Kumar S, Muchmore A. Tamm-Horsfall protein--uromodulin (1950-1990). *Kidney Int* 1990;**37**:1395–401.

Lagacé-Wiens P, Walkty A, Karlowsky J. Ceftazidime&amp;ndash;avibactam: an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections. *Core Evid* 2014;**9**:13.

Lambert PA. Mechanisms of antibiotic resistance in Pseudomonas aeruginosa. *J R Soc Med Sect Paediatr CHILD Heal* 2002;**95**:22–6.

Lee J, Zhang L. The hierarchy quorum sensing network in Pseudomonas aeruginosa. *Protein Cell* 2015;**6**:26–41.

Livermore DM. Of Pseudomonas, porins, pumps and carbapenems. *J Antimicrob Chemother* 2001;**47**:247–50.

Lister PD, Wolter DJ, Hanson ND. Antibacterial-Resistant Pseudomonas aeruginosa: Clinical Impact and Complex Regulation of Chromosomally Encoded Resistance Mechanisms. *Clin Microbiol Rev* 2009;**22**:582–610.

Lovewell RR, Patankar YR, Berwin B. Mechanisms of phagocytosis and host clearance of Pseudomonas aeruginosa. *AJP Lung Cell Mol Physiol* 2014;**306**:L591–603.

Mahenthiralingam E, Campbell ME, Speert DP. Nonmotility and phagocytic resistance of Pseudomonas aeruginosa isolates from chronically colonized patients with cystic fibrosis. *Infect Immun* 1994;**62**:596–605.

Marcus N, Ashkenazi S, Samra Z *et al.* Community-Acquired Pseudomonas aeruginosa Urinary Tract Infections in Children Hospitalized in a Tertiary Center: Relative Frequency, Risk Factors, Antimicrobial Resistance and Treatment. *Infection* 2008;**36**:421–6.

Mittal R, Sharma S, Chhibber S *et al.* Alteration in virulence characteristics of biofilm cells of Pseudomonas aeruginosa in presence of Tamm-Horsfall protein. *World J Microbiol Biotechnol* 2006;**22**:915–9.

Mittal R, Sharma S, Chhibber S *et al.* Iron dictates the virulence of Pseudomonas aeruginosa in urinary tract infections. *J Biomed Sci* 2008a;**15**:731–41.

Mittal R, Sharma S, Chhibber S *et al.* Contribution of free radicals to Pseudomonas aeruginosa induced acute pyelonephritis. *Microb Pathog* 2008b;**45**:323–30.

Mittal R, Sharma S, Chhibber S *et al.* Effect of Osmolarity on Virulence of Uropathogenic Pseudomonas Aeruginosa. *Am J Biomed Sci* 2009;**1**:12–26.

Morales E, Cots F, Sala M *et al.* Hospital costs of nosocomial multi-drug resistant Pseudomonas aeruginosa acquisition. *BMC Health Serv Res* 2012;**12**:122.

Muller M. Pyocyanin induces oxidative stress in human endothelial cells and modulates the glutathione redox cycle. *Free Radic Biol Med* 2002;**33**:1527–33.

Narten M, Rosin N, Schobert M *et al.* Susceptibility of Pseudomonas aeruginosa Urinary Tract Isolates and Influence of Urinary Tract Conditions on Antibiotic Tolerance. *Curr Microbiol* 2012;**64**:7–16.

Nicas TI, Iglewski BH. Production of elastase and other exoproducts by environmental isolates of Pseudomonas aeruginosa. *J Clin Microbiol* 1986;**23**:967–9.

Nicolle LE, Strausbaugh LJ, Garibaldi RA. Infections and antibiotic resistance in nursing homes. *Clin Microbiol Rev* 1996;9:1–17.

Nicolle LE. Complicated urinary tract infection in adults. *Can J Infect Dis Med Microbiol = J Can des Mal Infect la Microbiol medicale* 2005;**16**:349–60.

Ostroff RM, Vasil AI, Vasil ML. Molecular comparison of a nonhemolytic and a hemolytic phospholipase C from Pseudomonas aeruginosa. *J Bacteriol* 1990;**172**:5915–23.

Overhage J, Bains M, Brazas MD *et al.* Swarming of Pseudomonas aeruginosa is a complex adaptation leading to increased production of virulence factors and antibiotic resistance. *J Bacteriol* 2008;**190**:2671–9.

Pak J, Pu Y, Zhang ZT *et al.* Tamm-Horsfall protein binds to type 1 fimbriated Escherichia coli and prevents E. coli from binding to uroplakin Ia and Ib receptors. *J Biol Chem* 2001;**276**:9924–30.

Pamp SJ, Tolker-Nielsen T. Multiple roles of biosurfactants in structural biofilm development by Pseudomonas aeruginosa. *J Bacteriol* 2007;**189**:2531–9.

Papp-Wallace KM, Endimiani A, Taracila MA *et al.* Carbapenems: past, present, and future. *Antimicrob Agents Chemother* 2011;**55**:4943–60.

Pennica D, Kohr WJ, Kuang WJ *et al.* Identification of human uromodulin as the Tamm-Horsfall urinary glycoprotein. *Science* 1987;**236**:83–8.

Poole K. Multidrug efflux pumps and antimicrobial resistance in Pseudomonas aeruginosa and related organisms. *J Mol Microbiol Biotechnol* 2001;**3**:255–64.

Pobiega M, Maciag J, Pomorska-Wesolowska M *et al.* Urinary tract infections caused by Pseudomonas aeruginosa among children in Southern Poland: Virulence factors and antibiotic resistance. *J Pediatr Urol* 2016;**12**:36.e1-36.e6.

Pruijm M, Ponte B, Ackermann D *et al.* Associations of Urinary Uromodulin with Clinical Characteristics and Markers of Tubular Function in the General Population. *Clin J Am Soc Nephrol* 2016;**11**:70–80.

Raffi HS, Bates JM, Laszik Z *et al.* Tamm-Horsfall Protein Protects Against Urinary Tract Infection by Proteus Mirabilis. *J Urol* 2009;**181**:2332–8.

Rawat S, Prasad B. PREVALENCE AND CHARACTERIZATION OF VIRULENCE PROPERTIES OF PSEUDOMONAS AERUGINOSA FROM CLINICAL SAMPLES AND HOSPITAL ENVIRONMENT IN DEHRADUN. *Int J Biol Pharm Res Int J Biol Pharm Res J* 2015;**6**:491–9.

Reigstad CS, Hultgren SJ, Gordon JI. Functional Genomic Studies of Uropathogenic Escherichia coli and Host Urothelial Cells when Intracellular Bacterial Communities Are Assembled. *J Biol Chem* 2007;**282**:21259–67.

Rizek C, Fu L, dos Santos LC *et al.* Characterization of carbapenem-resistant Pseudomonas aeruginosa clinical isolates, carrying multiple genes coding for this antibiotic resistance. *Ann Clin Microbiol Antimicrob* 2014;**13**:43.

Rizvi M, Khan F, Shukla I *et al.* Rising prevalence of antimicrobial resistance in urinary tract infections during pregnancy: Necessity for exploring newer treatment options. *J Lab Physicians* 2011;**3**:98.

Rosenthal VD, Al-Abdely HM, El-Kholy AA *et al.* International Nosocomial Infection Control Consortium report, data summary of 50 countries for 2010-2015: Device-associated module. *Am J Infect Control* 2016;**44**:1495–504.

Rumbaugh K, Griswold J, Hamood A. Pseudomonas aeruginosa strains obtained from patients with tracheal, urinary tract and wound infection: variations in virulence factors and virulence genes. *J Hosp Infect* 1999;**43**:211–8.

Sakhtah H, Koyama L, Zhang Y *et al.* The Pseudomonas aeruginosa efflux pump MexGHI-OpmD transports a natural phenazine that controls gene expression and biofilm development. *Proc Natl Acad Sci U S A* 2016;**113**:E3538-47.

Sanna-Cherchi S, Sampogna RV, Papeta N *et al.* Mutations in *DSTYK* and Dominant Urinary Tract Malformations. *N Engl J Med* 2013;**369**:621–9.

Scott LJ. Ceftolozane/Tazobactam: A Review in Complicated Intra-Abdominal and Urinary Tract Infections. *Drugs* 2016;**76**:231–42.

Serafini-Cessi F, Malagolini N, Cavallone D. Tamm-Horsfall glycoprotein: biology and clinical relevance. *Am J Kidney Dis* 2003;**42**:658–76.

Seviour T, Hansen SH, Yang L *et al.* Functional amyloids keep quorum-sensing molecules in check. *J Biol Chem* 2015;**290**:6457–69.

Shand GH, Anwar H, Kadurugamuwa J *et al.* In vivo evidence that bacteria in urinary tract infection grow under iron-restricted conditions. *Infect Immun* 1985;**48**:35–9.

Sharma G, Rao S, Bansal A *et al.* Pseudomonas aeruginosa biofilm: Potential therapeutic targets. *Biologicals* 2014;**42**:1–7.

Stickler DJ, Morris NS, McLean RJ *et al.* Biofilms on indwelling urethral catheters produce quorum-sensing signal molecules in situ and in vitro. *Appl Environ Microbiol* 1998;**64**:3486–90.

Tielen P, Narten M, Rosin N *et al.* Genotypic and phenotypic characterization of Pseudomonas aeruginosa isolates from urinary tract infections. *Int J Med Microbiol* 2011;**301**:282–92.

Tielen P, Rosin N, Meyer A *et al.* Regulatory and metabolic networks for the adaptation of Pseudomonas aeruginosa biofilms to urinary tract-like conditions. *PLoS One* 2013;**8**:e71845.

Tielen P, Wibberg D, Blom J *et al.* Genome Sequence of the Small-Colony Variant Pseudomonas aeruginosa MH27, Isolated from a Chronic Urethral Catheter Infection. *Genome Announc* 2014;**2**, DOI: 10.1128/genomeA.01174-13.

Toder DS, Ferrell SJ, Nezezon JL *et al.* lasA and lasB genes of Pseudomonas aeruginosa: analysis of transcription and gene product activity. *Infect Immun* 1994;**62**:1320–7.

Toder DS, Gambello MJ, Iglewski BH. Pseudomonas aeruginosa LasA: a second elastase under the transcriptional control of lasR. *Mol Microbiol* 1991;**5**:2003–10.

Vikström E, Bui L, Konradsson P *et al.* The junctional integrity of epithelial cells is modulated by Pseudomonas aeruginosa quorum sensing molecule through phosphorylation-dependent mechanisms. *Exp Cell Res* 2009;**315**:313–26.

Visca P, Imperi F, Lamont IL. Pyoverdine siderophores: from biogenesis to biosignificance. *Trends Microbiol* 2007;**15**:22–30.

Wang J, Yu B, Tian D *et al.* Rhamnolipid but not motility is associated with the initiation of biofilm seeding dispersal of Pseudomonas aeruginosa strain PA17. *J Biosci* 2013;**38**:149–56.

Warren JW. Catheter-associated urinary tract infections. *Int J Antimicrob Agents* 2001;**17**:299–303.

WHO. GLOBAL PRIORITY LIST OF ANTIBIOTIC-RESISTANT BACTERIA TO GUIDE RESEARCH, DISCOVERY, AND DEVELOPMENT OF NEW ANTIBIOTICS. 2017.

Woods D, Schaffer M, Rabin H *et al.* Phenotypic comparison of Pseudomonas aeruginosa strains isolated from a variety of clinical sites. *J Clin Microbiol* 1986;**24**:260–4.

Woods DE, Cryz SJ, Friedman RL *et al.* Contribution of Toxin A and Elastase to Virulence of Pseudomonas aeruginosa in Chronic Lung Infections of Rats. *Infect Immun* 1982;**36**:1223–8.

Zaffanello M, Malerba G, Cataldi L *et al.* Genetic risk for recurrent urinary tract infections in humans: a systematic review. *J Biomed Biotechnol* 2010;**2010**:321082.

Zeng G, Vad BS, Dueholm MS *et al.* Functional bacterial amyloid increases Pseudomonas biofilm hydrophobicity and stiffness. *Front Microbiol* 2015;**6**:1099.

Zhanel GG, Chung P, Adam H *et al.* Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination with Activity Against Multidrug-Resistant Gram-Negative Bacilli. *Drugs* 2014;**74**:31–51.